Bcl-2 Double Nickase Plasmid (h): sc-400025-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Bcl-2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- Bcl-2 Double Nickase Plasmid (h) and Bcl-2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting BCL2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Bcl-2 Antibody (C-2): sc-7382
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Bcl-2 Double Nickase Plasmid (h) | sc-400025-NIC | 20 µg | $410.00 | |||
Bcl-2 Double Nickase Plasmid (h2) | sc-400025-NIC-2 | 20 µg | $410.00 |
Human BCL2 encodes the Bcl-2 protein, a central anti-apoptotic regulator that preserves mitochondrial outer membrane integrity and limits cytochrome c release. By restraining intrinsic apoptosis through interactions with pro-apoptotic BAX/BAK and BH3-only proteins, Bcl-2 influences caspase activation, cellular stress responses, and survival signaling. Altered BCL2 expression or regulation can shift the balance between survival and programmed cell death, impacting processes such as lymphocyte homeostasis and stress adaptation. Dysregulated Bcl-2 activity is frequently studied in the context of oncogenic survival, therapy resistance mechanisms, and apoptosis pathway remodeling in human disease models.
Bcl-2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the BCL2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within BCL2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt BCL2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of BCL2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.